Anixa Biosciences and OntoChem are developing an oral antiviral therapy for COVID-19. The fight against COVID-19 continues and another promising antiviral therapy is in development. While there is now a long list of antiviral drugs that are approved or under evaluation for the treatment of COVID-19, that hasn't stopped people from being skeptical about the effectiveness of current vaccines. Between the side effects and the unavailability of the vaccine, people have serious concerns that prevent them from getting vaccinated.
About 40% of Marines are reported to have chosen not to receive the COVID-19 vaccine. This surprisingly high number was cited for many reasons. Maybe some Marines allow other more vulnerable people to get it first, they could wait for it to become mandatory, or it could be because they are allergic to it.
However, officials say much of the doubts about the vaccine
stem from concerns about how quickly the vaccine was developed. They are not
sure about the long-term effects of the vaccine and therefore do not want to
take it. Fortunately, more and more research is being done on alternative
antiviral therapies.
The development phase of antiviral therapy
Anixa Biosciences and OntoChem Two recently announced that they are moving to the next stage of development of their room-temperature stable oral antiviral therapy against SARS-CoV-2, the virus that causes COVID-19. Two recently completed proof-of-concept studies on a model of the Syrian hamster virus.
Two potential compounds were appraised, as fine as
Remdesivir, which is currently the only FDA-approved treatment for COVID-19.
Dr. Amit Kumar, Premier, and CEO of Anixa Biosciences said: “Based on promising
preliminary data from animal research, we have decided to move to the next
phase of drug development. We have selected a compound around which we will
conduct combinatorial synthetic medicinal chemistry to assess whether we can
improve efficacy and optimize pharmacokinetics. The most promising compounds
will be re-evaluated in vitro and in vivo studies.
Anixa Biosciences is a publicly-traded biotech company that previously developed a cancer immunotherapy program as well as a COVID-19 treatment program. As for vaccines, the company has been working on a vaccine to prevent breast cancer. In particular, he focused on triple-negative breast cancer (TNBC), which is the deadliest form of the disease. They also worked on a vaccine to prevent ovarian cancer.
While its new COVID-19 antiviral treatment
is still in its early stages, developments are promising and the future looks
bright for anyone still concerned about the potential side effects of existing
COVID-19 vaccines. While it is certainly impressive that the Pfizer and Moderna
mRNA vaccines were developed in less than a year, it is understandable that
some people may be concerned about the long-term effects of these current
vaccines and look forward to future treatment options.